Skip to main content
Triangle logo TriangleGet started

Capivasertib (NCT05593497)

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss: a one-minute explainerNCT055934971 min

Capivasertib trial for High-Risk Prostate Cancer (NCT05593497). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with high-risk, nonmetastatic prostate cancer and PTEN staining of 10% or less, planning prostatectomy with lymph-node dissection.

The idea: block both androgen signaling and the AKT pathway. Patients start leuprolide and abiraterone with prednisone, have a research biopsy after four weeks, then add capivasertib for 16 weeks before surgery. Capivasertib tablets are taken twice daily, four days each week.

This phase 2 study plans 30 patients. Ryan Kopp at VA Portland leads the VA-sponsored study, with eight recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.